Almaarefa University
The authoritative source for research information and outputs is Elsevier Scopus, with researcher profile verification from the Deanship of Scientific Research.

المخرجات

Research outputs

Articles, reviews, conference papers and book chapters, indexed by DOI and linked to University researchers.

261 output Results for «Chemistry»

ArticleOpen access20263citation· Semantic Scholar

Development and Validation of a Robust RP‐HPLC Method for Quantifying Dasatinib in Self‐Microemulsifying Drug Delivery Systems

International Journal of Analytical Chemistry · vol. 2026 (1) · 4376722-4376722

Dasatinib, a therapy for chronic myeloid leukemia, suffers from poor bioavailability. Self‐microemulsifying drug delivery systems (SMEDDSs) are used to improve its dissolution. This study aimed to develop and validate a novel reverse‐phase high‐performance liquid chromatography (RP‐HPLC) method for quantifying dasatinib in SMEDDS formulations. The RP‐HPLC method utilized a mobile phase of methanol and 0.1% trifluoroacetic acid (55:45, v/v) and identified a peak wavelength for dasatinib at 324 nm. SMEDDS formulations comprised Capryol 90, Transcutol HP, and Tween 40. The method was validated according to ICH guidelines, demonstrating excellent linearity ( R 2 = 0.9993), accuracy (recovery between 98% and 101%), and precision (relative standard deviation of 0.73%). It also showed stability and reliability with limits of detection and quantification of 0.17 and 0.50 µg/mL, respectively. This RP‐HPLC method meets all validation criteria and provides a robust, cost‐effective tool for analyzing dasatinib in SMEDDS formulations.

dasatinibself-microemulsifying drug delivery systemRP-HPLC method developmentmethod validation
ReviewClosed20262citation· Semantic Scholar

USFDA‐Approved Small Molecules in the Year 2025: Medicinal Chemistry Strategies and Trends

Archiv der Pharmazie · vol. 359 (6) · e70272-e70272

Small-molecule-based therapeutics play a vital role in drug discovery. These molecules are preferred owing to their oral bioavailability, ease of tuning the physicochemical properties, and broad target accessibility. In this review article, we have explored the small molecules approved by the US Food and Drug Administration (USFDA) in 2025. Through the analysis, we found 44 drug approvals, out of which 30 candidates were approved as new molecular entities (NMEs), while the remaining 14 were approved in the category of biologics, including 10 approved as biosimilars. Considering the therapeutic area distribution of 30 NMEs, 28 drugs are approved as monotherapy, with 10 drugs as anticancer agents, 4 drugs for genetic disorders, 2 drugs each for the conditions of immunological, respiratory, ophthalmic, and endocrine disorders, along with the treatment of cardiac and infectious diseases. The structural diversity analysis revealed that 29 approved drugs were aromatic (azaheterocycles) in nature, and 13 drugs possess at least one stereogenic center. Considering the elemental diversity, the near-universal presence of nitrogen in the form of amines, amides, and as a heteroatom, followed by the oxygen atom. Additionally, the prevalence of 3- or 4-membered carbocyclic or heterocyclic rings was found in five approved drugs. For metabolism, most drugs rely on CYP3A-mediated metabolism, primarily through CYP3A4, CYP2D6, and CYP2C8. Collectively, the analysis and compilation of the drugs presented are expected to provide practical insights and offer guidance to medicinal chemists, biologists, and scientists associated with current drug-discovery paradigms, making continuous strides for future medicinal chemistry innovations and evolutions.

FDA-approved drugsnew chemical entitiessmall molecule drugsdrug discovery
ArticleClosed20262citation· Semantic Scholar

DFT and Molecular Dynamics Guided Pharmacokinetic Evaluation of Phenyl Styryl Ketone Derivatives as Potential MAO‐B Inhibitors

ChemistrySelect · vol. 11 (2)

ABSTRACT This research explores the capacity of phenyl styryl ketone derivatives to inhibit monoamine oxidase B (MAO‐B), a key enzyme associated with neurodegenerative disorders. From frontier molecular orbital (FMO) studies, reactivity parameters of the drug candidates were found out. Ligands were submitted to absorption, digestion, metabolism, excretion, and toxicity (ADMET) analysis to ensure their potential drugability and safety. To understand the electronic description of ligand interaction, natural bond orbital (NBO) analysis was conducted, and the presence of heteroatoms was proven crucial. The reduced density gradient (RDG) studies, together with molecular electrostatic surface potential (MESP) analysis, were able to provide the ligand's active sites and nature of interaction. Docking studies were conducted to study the interaction between the protein (P) and ligand (L) at the MAO‐B catalytic region, alongside a comparison with safinamide, a recognized MAO‐B inhibitor. Molecular dynamics (MD) simulations were utilized to examine the protein–ligand complex (PLC). The molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) method was applied to predict the binding affinity and interaction. We also analyzed structural stability, solvation, and decomposition. Of the four ligands examined, CHA_1.4 is found to be the most efficient. The contact map method was useful in identifying the key amino acids; in all the complexations we have considered, TYR398 has interacted most with the drug candidates. The finding was in agreement with the decomposition profile of the PLC. For the principal component analysis (PCA), topology formats and 100 ns MD trajectories are used to learn more about how proteins fold. Replicates were also done to validate the reported study and are represented as box‐whisker plots. The study's findings provide valuable insights for the development of new MAO‐B inhibitors.

monoamine oxidase B inhibitorsmonoamine oxidase Bneurodegenerative diseasesfrontier molecular orbitals
ArticleOpen access20262citation· Semantic Scholar

Identification of Apixaban as a Potential Inhibitor of the SARS‐CoV‐2 Main Protease: A Multistage Computational Study

Journal of Chemistry · vol. 2026 (1)

The SARS‐CoV‐2 main protease (M pro ) remains a critical therapeutic target for COVID‐19 intervention. In this study, we employed a comprehensive in silico repurposing strategy to identify FDA‐approved drugs with potential inhibitory activity against M pro . An initial molecular fingerprint screening of 3009 FDA‐approved compounds, based on similarity to the cocrystallized inhibitor X77, yielded 150 similar candidates. Subsequent structural similarity filtering reduced the list to 30 compounds, which were subjected to molecular docking. Apixaban demonstrated strong binding affinity and favorable interaction patterns within the M pro active site and was selected for further investigation. A 100‐ns molecular dynamics simulation comparing the apo and holo forms confirmed the structural stability of the M pro –apixaban complex. Apixaban remained stably positioned within the binding pocket, while reduced RMSF values in key active‐site residues indicated apixaban‐induced stabilization. Molecular mechanics–generalized Born surface area (MM‐GBSA) analysis estimated a binding free energy of −22.19 kcal/mol, with van der Waals interactions contributing predominantly to complex stability. Per‐residue decomposition highlighted significant contributions from Met165 and Gln189. Protein–ligand interaction fingerprinting (ProLIF) and protein–ligand interaction profiler (PLIP) analyses revealed persistent hydrogen bonds and hydrophobic contacts involving Asn142, Cys145, Gln189, Thr190, Gln192, and Arg188. Principal component analysis of trajectories (PCAT) demonstrated apixaban‐induced modulation of collective motions and partial closure of the binding pocket. Importantly, this study provides detailed atomistic insights into the potential interaction of apixaban with M pro . Together, these findings offer a plausible molecular rationale for its inhibitory activity and support further experimental and pharmacological evaluation of apixaban as a potential therapeutic candidate targeting SARS‐CoV‐2 M pro .

apixabanmain proteaseCOVID-19 pandemicdrug repurposing
ArticleOpen access20261citation· Semantic Scholar

L-Serine Attenuates Metabolic and Behavioural Features of Diabetic Neuropathy with Dose-Dependent Central Proteomic Correlates in a Rat Model

Biomolecules · vol. 16 (6) · 881-881

Diabetic neuropathy (DN) is a multifactorial complication of diabetes mellitus driven by chronic hyperglycemia, insulin resistance, and disturbed metabolic homeostasis, leading to progressive injury of both the peripheral and central nervous systems. This study investigated whether L-serine supplementation could attenuate DN through dose-dependent metabolic and neuroprotective mechanisms in a high-fat diet (HFD) plus streptozotocin (STZ)-induced diabetic rat model. Male Wistar rats (n = 8 per group) were allocated to five groups: normal control (NC), diabetic control (DC), pioglitazone (PIO; 1.5 mg/kg/day), low-dose L-serine (S1; 200 mg/kg/day), and high-dose L-serine (S2; 400 mg/kg/day). After 60 days of oral gavage, behavioural testing, glucose and insulin profiling, HOMA-IR calculation, brain histopathology, nerve growth factor (NGF) immunohistochemistry, and LC–MS/MS-based proteomic analysis of cerebral tissue were performed. Diabetic rats exhibited marked hyperglycaemia (355.33 ± 4.72 mg/dL), hyperinsulinaemia, severe insulin resistance (HOMA-IR 16.8 ± 3.2; a 14-fold increase), impaired thermal nociception, motor dysfunction, and pronounced neuronal degeneration. L-serine supplementation significantly improved metabolic status: S1 reduced HOMA-IR by 77.4% and S2 by 87.5% relative to diabetic controls (p < 0.001). High-dose L-serine produced greater improvements in thermal sensitivity, motor coordination (rotarod latency 26.67 ± 1.52 s vs. 16.1 ± 0.85 s in DC; p < 0.05), and NGF expression (8.6-fold increase vs. DC). Histopathology confirmed attenuation of neuronal injury and gliosis in both treatment groups. Exploratory, group-level proteomic profiling identified dose-specific molecular signatures: S1 was predominantly associated with carbohydrate, lipid, and biosynthetic pathways, whereas S2 was associated with synaptic, neurotransmission-related, and proteostasis pathways. Within the constraints of an exploratory design—group-level pooled proteomics, analysis of cerebral rather than peripheral-nerve tissue, and only two doses—these findings indicate that L-serine attenuates the metabolic and behavioural features of experimental diabetic neuropathy and generates the testable hypothesis of dose-dependent neuro-metabolic remodelling. The proteomic signatures are hypothesis-generating and require orthogonal validation before any mechanistic or translational inference can be drawn.

diabetic neuropathyinsulin resistancehyperglycemiastreptozotocin-induced diabetes
ArticleClosed2026

Elucidating the Therapeutic Mechanisms of Nickel(II)– Hydroazinecarbothioamide Complexes Across Cancer, Microbial, and Oxidative Stress Models

ChemistrySelect · vol. 11 (38)

ABSTRACT Isatin‐based ligands have been recognized for their remarkable pharmacological potential and this study reports the synthesis, characterization, and biological evaluation of three novel nickel(II)‐isatin hydrazone complexes ( C1–C3 ). The complexes were characterized by FT‐IR, UV–vis, mass spectroscopy, DFT, magnetic, conductivity and thermal analyses indicating octahedral geometry and appreciable heat stability. Molecular electrostatic potential mapping gave information on their electronic properties. DFT calculations indicated decreased HOMO–LUMO gaps indicating increased reactivity. Biological screening showed remarkable anticancer activity against HCT‐116, A549, MCF‐7, and HepG‐2 cell lines (IC 50 = 7.22–17.33 µM), potent antibacterial and antifungal activities comparable to ciprofloxacin and clotrimazole against Staphylococcus aureus and Candida albicans , and significant antioxidant activity with 59%–69% of the radical scavenging. Molecular docking and dynamics studies showed the stable binding interactions with the target enzyme FabH especially for complex C3 . These results collectively highlight C1‐C3 as multifunctional therapeutic candidates with stability and reactivity properties, making them attractive scaffolds for pharmacological development.

nickel(II) complexesanticancer activityantibacterial activityantifungal activity
ReviewOpen (repository)2026

Patient‐Derived Organoids in Functional Precision Oncology: Tumor Modeling, Drug‐Response Prediction, and Clinical Translation

Cell Biochemistry and Function · vol. 44 (10) · e70321-e70321

Patient-derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long-standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three-dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural, genomic, and phenotypic characteristics of their tumors of origin, enabling more accurate modeling of tumor heterogeneity and disease evolution. Over the last decade, rapid methodological advances in organoid culture systems, extracellular matrices (ECMs), and growth factor optimization have facilitated the establishment of organoid models for a wide range of malignancies and the development of large living biobanks representing diverse patient populations. These models are increasingly being utilized to study cancer biology, elucidate mechanisms of treatment resistance, and evaluate patient-specific therapeutic responses, highlighting their potential as tools for precision oncology. However, important challenges remain, including incomplete representation of the tumor microenvironment (TME), variability in culture conditions, and limited scalability, and the need for greater standardization and validation. Consequently, although PDOs show considerable promise for translational research and personalized medicine, their routine clinical implementation remains largely investigational, and their clinical utility has not yet been fully established. This review examines the technological foundations of PDO generation, assesses their role as experimental models of tumor biology, and discusses their expanding applications in translational cancer research and precision oncology while highlighting key challenges that must be addressed before their widespread clinical adoption.

patient-derived organoidsprecision oncologytumor heterogeneitydrug response prediction
ArticleOpen (repository)2026

Integrated in vitro and in silico evaluations of novel benzanilide derivatives as anticancer agents

Future Medicinal Chemistry · vol. 18 (19) · 2645-2662

Aims This study aimed to design, synthesize, and evaluate novel benzanilide derivatives as potential anticancer agents targeting VEGFR-2-mediated tumor angiogenesis.Materials and methods Eight benzanilide derivatives (7a-e, 9a-b, and 11) were synthesized and structurally confirmed using spectroscopic methods. The compounds were evaluated via molecular docking, in silico ADMET profiling, in vitro cytotoxicity against MCF-7, MDA-MB-231, HepG-2, and HCT-116 cancer cell lines, and selectivity assessment using WI-38 and WISH normal cell lines. VEGFR-2 enzyme inhibition was also determined for the most active compound.Results Compound 11 exhibited the highest cytotoxic activity with IC50 values of 6.08, 5.76, 7.94, and 4.64 µM against MCF-7, MDA-MB-231, HepG-2, and HCT-116, respectively, comparable to sorafenib. It showed potent VEGFR-2 inhibition (IC50 = 0.414 µM) superior to sorafenib (0.809 µM). Mechanistic studies indicated activation of apoptosis via upregulation of Bax, Caspase-3, and Caspase-8 and downregulation of Bcl-2. ADMET results revealed favorable pharmacokinetic properties and acceptable safety profiles.Conclusions Compound 11 represents a promising VEGFR-2 inhibitor with potent anticancer activity and favorable drug-like properties, warranting further optimization and development.

VEGFR-2 inhibitorsanticancer agentstumor angiogenesiscytotoxicity
ArticleClosed2026

Preventive effects of quercetin and N-acetylcysteine, alone and combined, against acetaminophen-induced hepatotoxicity in rats: associations with COX-2/TGF-β1 and Nrf2/HO-1 mRNA expression

Toxicology Research · vol. 15 (5)

Abstract This study evaluated the preventive effects of quercetin (QR) and N-acetylcysteine (NAC), alone or combined, in a rat model of acute acetaminophen (APAP)-induced hepatotoxicity. Twenty-five male rats were allocated to five groups (n = 5): control, APAP, NAC + APAP, QR + APAP, and NAC + QR + APAP. NAC (150 mg/kg) and/or QR (50 mg/kg) were administered orally for 7 days before a single oral APAP dose (2 g/kg). Serum liver-function indices, lipid profile, circulating TNF-α and IL-6, hepatic oxidative-status indices, hepatic COX-2, TGF-β1, Nrf2, and HO-1 mRNA abundance, histopathology, and IL-1β immunohistochemistry were assessed. APAP increased ALT, AST, triglycerides, total cholesterol, TNF-α, IL-6, and hepatic MDA, while decreasing total protein, albumin, HDL-C, GSH, CAT, SOD, and GPx. It also increased COX-2 and TGF-β1 transcripts and decreased Nrf2 and HO-1 transcripts. Pretreatment with NAC or QR partially attenuated these changes, whereas their combination generally produced values closer to control. The combined regimen also reduced histological injury and IL-1β immunoreactivity relative to APAP. These findings support a preventive association between combined NAC/QR exposure and improved redox and inflammatory indices. Because protein abundance, Nrf2 nuclear translocation, treatment after injury, and treatment-only controls were not evaluated, the data do not establish pathway activation, pharmacological synergy, or therapeutic efficacy after established overdose.

quercetinN-acetylcysteineacetaminophen hepatotoxicitydrug-induced liver injury
ArticleOpen (repository)2026

A Topological and Spatial Analysis of FDA‐Approved Drugs, Blood‐Brain Barrier Permeants, Natural Products, and Metabolites

ChemMedChem · vol. 21 (17) · e70462-e70462

In this study, we present a comprehensive structural analysis of four distinct chemical libraries: FDA‐approved drugs, blood‐brain barrier (BBB) permeable agents, natural products (UNPDA), and human metabolites. Our multidimensional profiling reveals fundamental divergences in molecular architecture. While synthetic drugs (FDA) and CNS‐active agents (BBB) follow continuous, Gaussian‐like distributions for carbon hybridization, natural products exhibit biosynthetic quantization, discrete, high‐intensity abundance spikes at C19 and C30, corresponding to steroid and triterpene scaffolds. Stereochemical analysis identifies a chirality‐structure lock in natural products, where stereoisomer density peaks significantly at these same integers (Avg. 3.53 isomers/mol), a complexity feature absent in the diffuse distribution of synthetic libraries. Topologically, we identify hyper‐globularity as a distinct signature for CNS permeability. Radial distribution function (RDF) analysis demonstrates that BBB agents possess a highly compressed aliphatic core, packing 93.2% of their sp 3 mass within a 3 Å radius, compared to 84.4% for general FDA therapeutics. Furthermore, elemental profiling reveals a heteroatom gap: synthetic drugs exhibit a high electronegative atom‐to‐carbon ratio (0.43), whereas BBB agents (0.33) converge with the lipophilic profile of natural products (0.32), suggesting that CNS penetration requires a biomimetic reduction in polarity. These findings establish new quantitative metrics for designing neuro‐compatible and biomimetic pharmacophores.

blood-brain barrier permeabilitynatural productshuman metabolitesFDA-approved drugs
ArticleClosed2026

The effect of losartan nanoparticles vs losartan on TIMP1 and α-SMA immunohistochemical and gene expression in carbon tetrachloride-induced liver fibrosis

Biotechnic & Histochemistry · vol. 101 (7) · 405-418

Liver fibrosis is characterized by scar formation as a response to injury. Although many drugs have demonstrated antifibrotic efficacy in vitro and in animal models, effectively translating these into effective clinical therapies remains a challenge. Nanotechnology offers potential therapeutic approaches for treating liver fibrosis. This study aimed to assess and compare the antifibrotic effects of losartan and losartan nanoparticles (LP-NPs) on CCl4-induced liver fibrosis in rats.Thirty-two adult male Sprague-Dawley rats were divided into four groups: a control group, a CCl4-induced fibrosis group, a losartan-treated group, and an LP-NPs-treated group. Liver fibrosis was induced by CCl4 injections over six weeks. Losartan or LP-NPs were orally administered for four weeks. At the conclusion of the study, rats were euthanized, and blood samples were collected for liver enzyme assessment. Liver specimens were subjected to histopathological examination (H&E, Sirius red staining), immunohistochemistry (α-SMA and TIMP1), and quantitative real-time PCR (qRT-PCR) for gene expression analysis of α-SMA and TIMP1. Morphometrical studies quantified collagen areas in Sirius red-stained sections and optical density of α-SMA and TIMP1 in immunohistochemically stained sections.The results showed that CCl4 induced significantly elevated liver enzymes, severe distortion of hepatic architecture, marked steatosis and fibrosis. Additionally, there was an increase in collagen content, accompanied by strong positive immunostaining and upregulated gene expression of α-SMA and TIMP1. Both losartan and LP-NPs treatments significantly improved these parameters compared to the CCl4-only group. Notably, LP-NPs demonstrated significantly greater improvements in liver enzyme levels, collagen percentage area, and the gene expression of α-SMA and TIMP1 compared to the standard losartan group. However, no significant difference was observed between the two treatments in α-SMA optical density.In conclusion, this investigation demonstrates that nanoformulation significantly enhanced losartan’s antifibrotic efficacy. LP-NPs improved liver function and histological architecture, reduced collagen content after CCl4 administration, and demonstrated greater therapeutic efficacy than conventional losartan.

losartanliver fibrosiscarbon tetrachlorideantifibrotic therapy
ArticleClosed2026

Integrated In Silico and In Vitro Discovery of a VEGFR-2-Targeted Anticancer Benzanilide Lead

Journal of Computational Biophysics and Chemistry · 1-20

The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.

VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
ArticleClosed2026

Development of a Novel Benzanilide Derivative Targeting VEGFR-2: Computational Modeling and In Vitro Anticancer Validation

Journal of Computational Biophysics and Chemistry · 1-20

The pursuit of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors continues to be a key approach in anticancer drug discovery. In this context, a new benzanilide-based derivative, Z-CMPBC, was designed following essential VEGFR-2 pharmacophoric requirements and investigated through combined computational and biological approaches. Density functional theory (DFT) calculations at the B3LYP/6-31[Formula: see text]G(d, p) level indicated favorable electronic characteristics, including balanced chemical hardness and pronounced electrophilicity, suggesting a strong propensity for interaction within kinase active sites. Molecular docking, supported by 200 ns molecular dynamics simulations, demonstrated stable accommodation of the compound within the VEGFR-2 binding pocket. Binding free energy calculations using the MM-GBSA method revealed a significant interaction profile ([Formula: see text] kcal/mol), mainly governed by van der Waals forces and persistent hydrophobic interactions with critical residues. Biological assessment confirmed potent VEGFR-2 inhibition, with an IC[Formula: see text] value of [Formula: see text]M, closely comparable to sorafenib ([Formula: see text]M). Western blot analysis further verified a reduction in phosphorylated VEGFR-2 (pY1054/Y1059) levels in MCF-7 cells, supporting effective intracellular kinase inhibition. Additionally, Z-CMPBC exhibited pronounced cytotoxicity, particularly against MCF-7 breast cancer cells (IC[Formula: see text]M), along with a high selectivity index ([Formula: see text]) relative to normal Vero cells. Flow cytometry analysis demonstrated induction of G0/G1 phase arrest, accompanied by enhanced apoptotic activity (34.05%) compared to untreated cells. In silico ADMET and toxicity predictions suggested acceptable pharmacokinetic behavior and safety characteristics. Overall, these findings highlight Z-CMPBC as a promising VEGFR-2 inhibitor with potential for further development as an anticancer agent.

VEGFR-2 inhibitorsanticancer drug discoverykinase inhibitorsMCF-7 cells